Sales & Support: +44 (0)1223 316 855

SARS-CoV-2 and the inflammatory storm: studies and literature

SARS-CoV-2 and complement therapeutics studies
•  Eculizumab (Soliris) in COVID-19 infected patients (SOLID-C19)
Alexion to study Ultomiris for COVID-19 treatment
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
InflaRx starts dosing COVID-19 patients in Europe
Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation

SARS-CoV-2 and complement literature
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases   
Coronaviruses hijack the complement system
Complement as a target in COVID-19?
Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis
Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV
Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV

SARS-CoV-2 and thromboinflammation/lung injury literature
Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach
Thrombomodulin in disseminated intravascular coagulation and other critical conditions - a multi-faceted anticoagulant protein with therapeutic potential:
Soluble thrombomodulin Increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: role of neutrophil elastase
Thrombomodulin favors leukocyte microvesicle fibrinolytic activity, reduces NETosis and prevents septic shock-induced coagulopathy in rats